Radiofrequency ablation will lead tumour ablation devices sales through 2036 with 39.7% share of the product type segment in 2026, driven by rising cancer incidence and expanding clinical adoption of minimally invasive treatment approaches. The market was valued at USD 2.20 billion in 2025 and is expected to be worth USD 9.12 billion by 2036.